Ighv3-66*01 (81.4%) -(Ighd) -Ighj1*01 (100%), Cdr-Imgt [8.7.6] (26-33.51-57.96-101)) (1-112) -Homo Sapiens Ighg1*03V, G1M3>G1M17, Ng1M1 Ch1 K120, Ch3 E12, M14, 8-G1V29 Ch2 A84.4 (Ch1 R120>K (209) (113-210), Hinge 1-15 (211-225), Ch2 N84.4>A (292) (226-335), Ch3 E12 (351), M14 (353) (336-440), Chs (441-442)) (113-442)], (215-216')-Disulfide With L-Kappa Light Chain Humanized (1'-216') [V-Kappa (Homo Sapiens Igkv1-5*01 (85.4%) -Igkj1*01 (90.0%) Q120>G (102'), Cdr-Imgt [7.3.10] (27'-33'.51'-53'.90'-99')) (1'-109') -Homo Sapiens Igkc*01 (100%) Km3 A45.1, V101 (C-Kappa A45.1 (155'), V101 (193')) (110'-216')]; Dimer (221-221'':224-224'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-Dg44, Non-Glycosylated
Migraine Disorder
Explore 101 assets in Migraine Disorder →Floatz Rating
B61/100
Confidence
Indicative
Sponsor
H. Lundbeck A/S
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06578585CT.gov A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine | — | Completed | — | — | — |
NCT06323928CT.gov A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments | — | Completed | — | — | — |
NCT05304910CT.gov A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants | — | Completed | — | — | — |
NCT05133323CT.gov A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Migraine Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ighv3-66*01 (81.4%) -(Ighd) -Ighj1*01 (100%), Cdr-Imgt [8.7.6] (26-33.51-57.96-101)) (1-112) -Homo Sapiens Ighg1*03V, G1M3>G1M17, Ng1M1 Ch1 K120, Ch3 E12, M14, 8-G1V29 Ch2 A84.4 (Ch1 R120>K (209) (113-210), Hinge 1-15 (211-225), Ch2 N84.4>A (292) (226-335), Ch3 E12 (351), M14 (353) (336-440), Chs (441-442)) (113-442)], (215-216')-Disulfide With L-Kappa Light Chain Humanized (1'-216') [V-Kappa (Homo Sapiens Igkv1-5*01 (85.4%) -Igkj1*01 (90.0%) Q120>G (102'), Cdr-Imgt [7.3.10] (27'-33'.51'-53'.90'-99')) (1'-109') -Homo Sapiens Igkc*01 (100%) Km3 A45.1, V101 (C-Kappa A45.1 (155'), V101 (193')) (110'-216')]; Dimer (221-221'':224-224'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-Dg44, Non-Glycosylated (this asset) | H. Lundbeck A/S | P2 | B · 61 |
| Atogepant | Stanford University | P4 | A |
| Zolmitriptan | Zosano Pharma Corporation | P4 | A |
| Naproxen | IRCCS San Raffaele Roma | P4 | A |
| Rizatriptan | Antonios Likourezos | P4 | A |
| Eptinezumab | Stanford University | P4 | BBB |
| Ubrogepant | H. Lundbeck A/S | P4 | BBB |
| Dfn-11 (Sumatriptan Injection) | IRCCS San Raffaele Roma | P4 | BBB |
| Eletriptan | Boehringer Ingelheim | P4 | BBB |
+42 more in the Migraine Disorder cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ighv3-66*01 (81.4%) -(Ighd) -Ighj1*01 (100%), Cdr-Imgt [8.7.6] (26-33.51-57.96-101)) (1-112) -Homo Sapiens Ighg1*03V, G1M3>G1M17, Ng1M1 Ch1 K120, Ch3 E12, M14, 8-G1V29 Ch2 A84.4 (Ch1 R120>K (209) (113-210), Hinge 1-15 (211-225), Ch2 N84.4>A (292) (226-335), Ch3 E12 (351), M14 (353) (336-440), Chs (441-442)) (113-442)], (215-216')-Disulfide With L-Kappa Light Chain Humanized (1'-216') [V-Kappa (Homo Sapiens Igkv1-5*01 (85.4%) -Igkj1*01 (90.0%) Q120>G (102'), Cdr-Imgt [7.3.10] (27'-33'.51'-53'.90'-99')) (1'-109') -Homo Sapiens Igkc*01 (100%) Km3 A45.1, V101 (C-Kappa A45.1 (155'), V101 (193')) (110'-216')]; Dimer (221-221'':224-224'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-Dg44, Non-Glycosylated in Migraine Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ighv3-6601-814-ighd-ighj101-100-cdr-imgt-876-26-3351-5796-101-1-112-homo-sapiens-ighg103v-g1m3g1m17-ng1m1-ch1-k120-ch3-e12-m14-8-g1v29-ch2-a844-ch1-r120k-209-113-210-hinge-1-15-211-225-ch2-n844a-292-226-335-ch3-e12-351-m14-353-336-440-chs-441-442-113-442-215-216-disulfide-with-l-kappa-light-chain-humanized-1-216-v-kappa-homo-sapiens-igkv1-501-854-igkj101-900-q120g-102-cdr-imgt-7310-27-3351-5390-99-1-109-homo-sapiens-igkc01-100-km3-a451-v101-c-kappa-a451-155-v101-193-110-216-dimer-221-221224-224-bisdisulfide-produced-in-chinese-hamster-ovary-cho-cells-cell-line-cho-dg44-non-glycosylated-migraine-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →